Skip to Main Content

Paper Details

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
Mol Syst Biol
43
2018
BRAF, CDK2, Hsp90, MEK, MITF, PDX, XL888, dinaciclib, melanoma, melanoma cell lines, melanomas, patient, patients, unresponsive cell lines
Author NameAffiliation
Johan Bostr??mKarolinska Institutet
Jonathan L RobinsonChalmers University of Technology
Fredrik EdforsKTH Royal Institute of Technology
Kristel KemperThe Netherlands Cancer Institute
Oscar KrijgsmanThe Netherlands Cancer Institute
Daniel S PeeperThe Netherlands Cancer Institute
Jens NielsenChalmers University of Technology
Jens NielsenChalmers University of Technology
Mikael AltunKarolinska Institutet
Mathias Uhl??nKTH Royal Institute of Technology
Mathias Uhl??nKTH Royal Institute of Technology
  • 1 - 11

Datasets

Release 1.2